Microscopic view of T cells interacting with Trypanosoma cruzi parasites.

Chagas Disease: Can Monitoring Immune Response Improve Treatment?

Author's portrait.
Avery Sinclair in Health & Wellness December 2025 • 5 min read.

"Research suggests tracking CD4+CD25+ T cells could offer insights into disease progression and treatment strategies for Chagas disease."


Chagas disease (ChD), caused by the parasite Trypanosoma cruzi, manifests differently in individuals. Some remain asymptomatic (indeterminate form - IND), while others develop severe cardiac (CARD) or digestive complications. The reasons behind these varying disease courses are complex, but an overactive immune response is thought to contribute to the tissue damage seen in symptomatic individuals.

Within the immune system, CD4+CD25+ T lymphocytes, a specialized group of cells, play a crucial role in regulating the body's immune response. These cells, characterized by the presence of the CD25 marker and the FoxP3 transcription factor, are believed to temper the cytotoxic activity that can harm the body in chronic ChD.

Recent efforts to develop recombinant T. cruzi antigens (CRA and FRA) offer new tools to study these immune responses. This article delves into a study that investigates the dynamics of CD4+CD25+ T cells in Chagas disease patients when stimulated with these recombinant antigens, potentially revealing new ways to understand and manage the disease.

Decoding the Immune Response: What the Study Revealed

Microscopic view of T cells interacting with Trypanosoma cruzi parasites.

In a study published in the Revista da Sociedade Brasileira de Medicina Tropical, researchers Suellen Carvalho de Moura Braz, Virginia Maria Barros de Lorena, and others examined the CD4+CD25+ T cell response in chronic Chagas disease patients. The team cultured peripheral blood mononuclear cells (PBMCs) from patients with both the indeterminate (IND) and cardiac (CARD) forms of ChD, exposing them to T. cruzi recombinant antigens CRA and FRA.

The key objective was to assess the presence of CD4+CD25+ T cells, specifically those expressing FoxP3, IL-10, and TGF-β, at different time points after stimulation. Blood samples were taken from patients diagnosed with chronic Chagas disease (6 with indeterminate form and 5 with cardiac complications).

  • PBMCs were isolated and cultured with recombinant CRA and FRA antigens.
  • The cells were incubated for 1, 3, and 5 days.
  • Flow cytometry was used to measure CD4+CD25+ T cells expressing FoxP3, IL-10, and TGF-β.
  • Supernatants were collected to measure TGF-β production.
While the study didn't find statistically significant differences in the overall CD4+CD25+ T cell populations across all time points, some interesting trends emerged. Most notably, the ability to differentiate between clinical forms of chronic Chagas disease was observed at days 3 and 5, according to the presence of CD4+CD25+ T cells in the cell cultures. In IND patients, the number of these cells tended to increase over the culture period, especially after stimulation with FRA. Conversely, in CARD patients, the number tended to decrease. Furthermore, the research indicated that longer cell culture periods (days 3 and 5) could be valuable for evaluating CD4+CD25+ T lymphocytes in chronic Chagas disease patients.

Future Directions: Can Immune Monitoring Improve Chagas Disease Management?

The study highlights the potential of monitoring CD4+CD25+ T cell responses in Chagas disease patients to understand disease progression. It suggests that the balance between these regulatory T cells and the overall immune response could be critical in determining whether an individual remains asymptomatic or develops severe complications.

While the study didn't definitively identify CD4+CD25+FoxP3+ T cells as the source of TGF-β, it paves the way for future research to explore this connection. Further investigation into the role of these cells and their secreted factors could reveal new therapeutic targets for modulating the immune response in Chagas disease.

Longer cell culture times might offer a more refined understanding of the dynamics of T cell populations, leading to more precise diagnostic and prognostic tools. This research underscores the importance of continued exploration into the immune mechanisms underlying Chagas disease to improve patient outcomes.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.1590/0037-8682-1323-2013, Alternate LINK

Title: Evaluation Of Cd4+Cd25+ T Lymphocyte Response Time Kinetics In Patients With Chronic Chagas Disease After In Vitro Stimulation With Recombinant Trypanosoma Cruzi Antigens

Subject: Infectious Diseases

Journal: Revista da Sociedade Brasileira de Medicina Tropical

Publisher: FapUNIFESP (SciELO)

Authors: Suellen Carvalho De Moura Braz, Virginia Maria Barros De Lorena, Adriene Siqueira Melo, Maria Da Gloria Aureliano Melo Cavalcanti, Yara De Miranda Gomes

Published: 2013-05-10

Everything You Need To Know

1

What is Chagas disease and how does it affect people?

Chagas disease is caused by the parasite *Trypanosoma cruzi*. It can manifest in different ways in individuals, some of whom remain asymptomatic (indeterminate form - IND), while others develop severe cardiac (CARD) or digestive complications. The immune system's response to the parasite is crucial in determining the disease's progression. An overactive immune response is believed to contribute to the tissue damage observed in symptomatic individuals.

2

What are CD4+CD25+ T lymphocytes, and what is their role?

CD4+CD25+ T lymphocytes are a specialized group of cells within the immune system that regulate the body's immune response. These cells, characterized by the presence of the CD25 marker and the FoxP3 transcription factor, are believed to temper the cytotoxic activity that can harm the body in chronic Chagas disease. They play a crucial role in determining whether an individual remains asymptomatic or develops severe complications.

3

How did the researchers study the immune response in Chagas disease?

Researchers used recombinant *T. cruzi* antigens, CRA and FRA, to stimulate the CD4+CD25+ T cells in patients with chronic Chagas disease. They cultured peripheral blood mononuclear cells (PBMCs) from patients with both the indeterminate (IND) and cardiac (CARD) forms of ChD, exposing them to the antigens. The study assessed the presence of CD4+CD25+ T cells expressing FoxP3, IL-10, and TGF-β at different time points after stimulation.

4

What were the key findings of the study regarding CD4+CD25+ T cells?

The study found that the ability to differentiate between clinical forms of chronic Chagas disease was observed at days 3 and 5 based on the number of CD4+CD25+ T cells in the cell cultures. In IND patients, the number of these cells tended to increase, especially after stimulation with FRA. Conversely, in CARD patients, the number tended to decrease. This suggests that monitoring CD4+CD25+ T cell responses could help to understand the progression of Chagas disease and differentiate between clinical forms.

5

How could monitoring immune responses help manage Chagas disease?

Monitoring CD4+CD25+ T cell responses could improve Chagas disease management by offering insights into disease progression and treatment strategies. The balance between these regulatory T cells and the overall immune response is critical in determining whether an individual remains asymptomatic or develops severe complications. Understanding these dynamics could lead to more targeted interventions.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.